BriaCell Announces Proposed Effective Date of Share Consolidation
BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company, has announced a 1-for-10 share consolidation to maintain Nasdaq listing compliance. The consolidation is expected to take effect on August 25, 2025, with post-consolidation trading beginning around August 26, 2025, subject to TSX and Nasdaq approval.
Under the consolidation terms, shareholders will receive one new share for every ten existing shares. Fractional shares will be handled by rounding up fractions of 陆 or greater to one whole share, while smaller fractions will be cancelled. The company's convertible securities will be proportionally adjusted, and trading symbols will remain unchanged on both exchanges.
BriaCell Therapeutics (NASDAQ: BCTX), una societ脿 biotecnologica in fase clinica, ha annunciato una consolidazione azionaria 1-per-10 per mantenere la conformit脿 alla quotazione Nasdaq. La consolidazione dovrebbe entrare in vigore il 25 agosto 2025, con l'inizio delle negoziazioni post-consolidamento previsto intorno al 26 agosto 2025, subordinatamente all'approvazione di TSX e Nasdaq.
Secondo i termini della consolidazione, gli azionisti riceveranno una nuova azione per ogni dieci azioni possedute. Le azioni frazionarie saranno gestite arrotondando per eccesso le frazioni pari o superiori a 陆 a un'azione intera, mentre le frazioni inferiori saranno annullate. I titoli convertibili della societ脿 saranno adeguati proporzionalmente e i simboli di negoziazione rimarranno invariati su entrambe le borse.
BriaCell Therapeutics (NASDAQ: BCTX), una empresa biotecnol贸gica en etapa cl铆nica, ha anunciado una consolidaci贸n de acciones 1 por 10 para mantener el cumplimiento de la cotizaci贸n en Nasdaq. Se espera que la consolidaci贸n entre en vigor el 25 de agosto de 2025, con el inicio de la negociaci贸n post-consolidaci贸n alrededor del 26 de agosto de 2025, sujeto a la aprobaci贸n de TSX y Nasdaq.
Bajo los t茅rminos de la consolidaci贸n, los accionistas recibir谩n una acci贸n nueva por cada diez acciones existentes. Las acciones fraccionarias se manejar谩n redondeando hacia arriba las fracciones de 陆 o m谩s a una acci贸n completa, mientras que las fracciones menores se cancelar谩n. Los valores convertibles de la compa帽铆a se ajustar谩n proporcionalmente y los s铆mbolos de negociaci贸n permanecer谩n sin cambios en ambas bolsas.
BriaCell Therapeutics (NASDAQ: BCTX)電� 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 雮橃姢雼� 靸侅灔 攴滌爼 欷�靾橂ゼ 鞙勴暣 1欤茧嫻 10欤� 頃╇硲鞚� 氚滍憸頄堨姷雼堧嫟. 頃╇硲鞚� 2025雲� 8鞗� 25鞚�鞐� 鞁滍枆霅� 鞓堨爼鞚措┌, 頃╇硲 頉� 瓯半灅電� TSX鞕� 雮橃姢雼レ潣 鞀轨澑鞐� 霐半澕 2025雲� 8鞗� 26鞚缄步 鞁滌瀾霅� 鞓堨爼鞛呺媹雼�.
頃╇硲 臁瓣贝鞐� 霐半澕 欤检＜霌れ潃 旮办〈 10欤茧嫻 1欤检潣 鞁犾＜毳� 氚涥矊 霅╇媹雼�. 陆欤� 鞚挫儊鞚� 靻岇垬 欤检嫕鞚� 1欤茧 氚橃槵毽� 觳橂Μ霅橂┌, 攴鸽炒雼� 鞛戩潃 靻岇垬 欤检嫕鞚� 靻岆└霅╇媹雼�. 須岇偓鞚� 鞝勴櫂歃濌秾霃� 牍勲鞝侅溂搿� 臁办爼霅橂┌, 霊� 瓯半灅靻� 氇憪鞐愳劀 瓯半灅 鞁臣鞚� 氤�瓴诫悩歆� 鞎婌姷雼堧嫟.
BriaCell Therapeutics (NASDAQ : BCTX), une soci茅t茅 biotechnologique en phase clinique, a annonc茅 une consolidation d鈥檃ctions au ratio de 1 pour 10 afin de maintenir sa conformit茅 avec les exigences de cotation du Nasdaq. La consolidation devrait entrer en vigueur le 25 ao没t 2025, avec un d茅but des 茅changes post-consolidation aux alentours du 26 ao没t 2025, sous r茅serve de l鈥檃pprobation de la TSX et du Nasdaq.
Selon les modalit茅s de la consolidation, les actionnaires recevront une nouvelle action pour dix actions existantes. Les fractions d鈥檃ctions seront arrondies 脿 l鈥檜nit茅 sup茅rieure si elles sont 茅gales ou sup茅rieures 脿 陆, les fractions inf茅rieures seront annul茅es. Les titres convertibles de la soci茅t茅 seront ajust茅s proportionnellement et les symboles de n茅gociation resteront inchang茅s sur les deux places boursi猫res.
BriaCell Therapeutics (NASDAQ: BCTX), ein Biotechnologieunternehmen in der klinischen Phase, hat eine Aktienzusammenlegung im Verh盲ltnis 1 zu 10 angek眉ndigt, um die Nasdaq-Listenanforderungen einzuhalten. Die Zusammenlegung soll am 25. August 2025 wirksam werden, wobei der Handel nach der Zusammenlegung voraussichtlich ab dem 26. August 2025 beginnt, vorbehaltlich der Genehmigung durch TSX und Nasdaq.
Gem盲脽 den Bedingungen der Zusammenlegung erhalten Aktion盲re f眉r jeweils zehn bestehende Aktien eine neue Aktie. Bruchst眉cke von Aktien werden aufgerundet, wenn sie 陆 oder mehr betragen, andernfalls entfallen sie. Die wandelbaren Wertpapiere des Unternehmens werden anteilig angepasst, und die Handelssymbole bleiben an beiden B枚rsen unver盲ndert.
- Share consolidation helps maintain Nasdaq listing compliance
- Clear 1:10 consolidation ratio provides certainty to shareholders
- Rounding up of fractional shares 鈮� 陆 benefits small shareholders
- Significant reduction in total outstanding shares may impact trading liquidity
- Shareholders with less than 陆 share post-consolidation will lose their holdings
Insights
BriaCell's 1:10 share consolidation aims to maintain Nasdaq compliance, effectively reducing share count while preserving proportional ownership.
BriaCell Therapeutics is implementing a 1-for-10 share consolidation to ensure continued compliance with Nasdaq listing requirements. This reverse split, expected to take effect on August 25, 2025, will proportionally reduce the number of outstanding shares while maintaining each shareholder's relative ownership percentage.
This type of corporate action typically occurs when a company needs to boost its share price to meet exchange minimum price requirements. While the consolidation changes the share count and price, it doesn't fundamentally alter the company's market capitalization or intrinsic value.
For shareholders, this means each position will be adjusted accordingly - every 10 shares currently owned will convert to 1 share post-consolidation. The post-consolidation shares will continue trading under the same symbols (BCT on TSX and BCTX on Nasdaq). Fractional shares will be handled with a standard rounding mechanism - fractions below 0.5 will be canceled while those 0.5 or above will be rounded up to a whole share.
Any convertible securities (options, warrants, etc.) will also see their exercise prices and issuable shares adjusted proportionally. Registered shareholders will receive instructions from Computershare for exchanging their shares, while beneficial holders who own shares through brokerages need not take action as their positions will adjust automatically.
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (鈥�BriaCell鈥� or the 鈥�Company鈥�), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company鈥檚 board of directors has approved the consolidation (the 鈥�Consolidation鈥�) of the Company鈥檚 issued and outstanding common shares (the 鈥�Common Shares鈥�) on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the 鈥�Nasdaq鈥�).
The Consolidation is subject to approval by the Toronto Stock Exchange (the 鈥�TSX鈥�) and Nasdaq and is expected to become effective on August 25, 2025 (the 鈥�Effective Date鈥�), with the post-Consolidation Common Shares commencing trading on the TSX and the Nasdaq at market open on or about August 26, 2025, subject to final confirmation from the TSX and the Nasdaq. No fractional Common Shares will be issued in connection with the Consolidation. Any fractional Common Shares remaining after the Consolidation that are less than 陆 of a Common Share will be cancelled, and each fractional Common Share that is at least 陆 of a Common Share will be rounded up to one whole Common Share. The Company does not intend to round up fractional shares at the beneficial level and will instead round any such fractional shares up at the participant level.听The exercise or conversion price and/or the number of Common Shares issuable under any of the Company鈥檚 outstanding convertible securities will be proportionately adjusted in connection with the Consolidation.
It is anticipated that upon completion of the Consolidation, the post-Consolidation Common Shares will continue to trade on the TSX under the symbol 鈥�BCT鈥� and on the Nasdaq under the symbol 鈥�BCTX鈥�.
Shareholders of record as of the Effective Date will receive a letter of transmittal from Computershare Investor Services Inc., the transfer agent for the Common Shares, providing instructions for the exchange of their Common Shares as soon as practicable following the Effective Date.
Registered shareholders may also obtain a copy of the letter of transmittal by accessing the Company鈥檚 SEDAR+ profile at . Until surrendered, each share certificate or direct registration system statement representing pre-Consolidation Common Shares will represent the number of whole post-Consolidation Common Shares to which the holder is entitled as a result of the Consolidation. No action is required by beneficial holders to receive post-Consolidation Common Shares in connection with the Consolidation. Beneficial holders who hold their Common Shares through intermediaries (e.g., a broker, bank, trust company investment dealer or other financial institution) and who have questions regarding how the Consolidation will be processed should contact their intermediaries with respect to the Consolidation.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at .
Safe Harbor
This press release contains 鈥渇orward-looking statements鈥� that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渟eek,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渢arget,鈥� 鈥渁im,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell鈥檚 current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 鈥淩isks and Uncertainties鈥� in the Company鈥檚 most recent Management鈥檚 Discussion and Analysis, under the heading 鈥淩isk Factors鈥� in the Company鈥檚 most recent Annual Information Form, and under 鈥淩isks and Uncertainties鈥� in the Company鈥檚 other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at 听and on EDGAR at . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
听
Investor Relations Contact:
FAQ
When will BriaCell's (BCTX) share consolidation take effect?
What is the ratio for BriaCell's (BCTX) share consolidation in 2025?
How will BriaCell (BCTX) handle fractional shares in the 2025 consolidation?
Why is BriaCell (BCTX) implementing a share consolidation in 2025?
Will BriaCell's stock symbol change after the 2025 consolidation?
